
|Articles|October 1, 2005
NSAID approved for cataract pain
After a priority 6-month review, the FDA approved nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories), a novel nonsteroidal anti-inflammatory prodrug, for the treatment of pain and inflammation associated with cataract surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocumetics reports first-in-human data investigational accommodating IOL in severe vision loss
2
EnVision Summit 2026: Ultimate gathering place for ophthalmic education
3
Sandoz Canada launches aflibercept biosimilar, Enzeevum
4
Noninvasive LED light therapy shows long-term safety in early cataract clinical follow-up
5




























